Investor Relations

For information regarding Silence's intellectual property portfolio, please visit the Platform Technologies section.

Stay up to date with our development alerts

>

Submit


DownloadSilence’s Circular April 2013

Silence Therapeutics plc (LSE: SLN) is a global leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases.

The company possesses one of the world’s most comprehensive RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features – the three areas the company believes to be critical to building, protecting and commercialising RNAi therapeutics.

The Company’s lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Silence’s product portfolio and technology platforms are protected by a strong intellectual property portfolio.

Share Price

208.00p

(-6.875p)

Vol:3600

15-minute delayed


For an updated stock quote, please access the link above to the London Stock Exchange


Registrars

Capita IRG plc
The Registry
34 Beckenham Road,
Kent,
BR3 4TU

Tel: +44 (0) 871 664 0300
Email: ssd@capitaregistrars.com


Financial Advisors

Canaccord Genuity Limited
88 Wood Street,
London,
EC2V 7QR

Tel: +44 20 7523 8321



Silence Therapeutics News & Articles on Proactiveinvestors

In the News